Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
To be honest I don't remember.
Need to look back.
I think Asim mentioned that the work was in Chennai didn’t he?
Taiwan
Aesthetic Medicine World Congress ASIA & Taiwan Dermatology Aesthetic Conference 2023
Sunday, 7 May 2023
Anti-aging in the era of aesthetics
SESSION PRESENTATION
Studies on Anti-aging and cardioprotective effect of tomato extract (FruitFlow®) on cardiomyoblast cells H9C2 (2-1)
Surajit PATHAK
https://agenda.euromedicom.com/global/o/amwc-asia-2023/2023-05-07/6400
Surajit PATHAK
Biologist / Biochemist
INDIA
Dr. Surajit Pathak is an Indian-born research scientist, advisor, and Professor at CHETTINAD ACADEMY OF RESEARCH AND EDUCATION, Chennai who has multiple expertise encompassing cancer biology, stem cell, and regenerative medicine. He started active research in the year 2001 and received his Ph.D. from INDIA in 2007. Worked in USA, Italy, and Sweden for over 10 years with 1800 citations. Dr. Pathak has published over 120 papers to date.
https://agenda.euromedicom.com/global/o/amwc-asia-2023/speaker/95093-pathak-surajit
https://www.linkedin.com/in/dr-surajit-pathak-3483972a/?originalSubdomain=in
He has contributed on published articles that include Fruitflow.
Bioactive food components and their inhibitory actions in multiple platelet pathways
https://onlinelibrary.wiley.com/doi/10.1111/jfbc.14476
In the absence of any facts or news it’s all we can do :)
All good speculation. Back to the dot joining days ehh !
You may recall this article from 2019. It is regarding By-Health and their grand goal of Healthy China 2030 and their partnership with BASF, Fonterra Limited and DuPont Nutrition & Health, to carry out healthy-ageing and nutrition research.
https://www.xinyingyang.com/content-25-13298-1.html
This happens to be around the same time that BH and PXS entered a collaboration agreement for PXS.
So, although I have not really seen any other evidence for this, I think By-Health, DuPont, Fronterra and BASF are all working on the healthy ageing research together for the ultimate goal of Healthy China 2030. This would surely include Fruitflow?
These are all mega-companies with huge global reach.
Then there are all the other research agencies, universities, hospitals etc that they are working with to carry out trials and present the data. It all paints a positive picture.
But, as always... WTFDIK
DSM are highlighting ‘A unique science-backed and multi-ingredient approach to health from the gut’ at Vitafoods Europe 2023.
I did wonder lol.
Bit of a senior moment in my previous post
first para should have ended "seems likely" rather than unlikely
The write up is brilliant, science presented in an understandable way.
Good to see activity in the USA, it should have happened a long time ago, but the new gut biota angle give the opportunity to put it before the industry afresh.
Those trades were marked as "PRIC". Can't be 100% sure, but that suggests they were a negogiated transfer. They were definitely negogiated though ( that's what "PRIC" means ) and they were Off-Book, so some sort of transfer seems unlikely.
As an aside, the flags on the large transaction the other week were quite different. Again, it's not possible to be totally sure, but that looked like a sale rather than a transfer.
BB
Not sure what has changed , ....https://patentscope.wipo.int/search/en/detail.jsf?docId=JP390583921&_cid=P21-LH82JE-21704-1
We will probably never find out but my best guess would be someone moving 14 million shares from one account to another. Whatever it was I don't think it was a buy or a sell.
BWTFDIK.
Happy for all the exposure Atlantia is giving Fruitflow atm including this recent article in teknoscienze
https://digital.teknoscienze.com/agrofood_industry_hi_tech_34_1_2023/company_profile_-_atlantia_clinical_trials
but it should be DSM that is publicising the benefits of Fruitflow at reducing TMAO.
Atlantia are sponsors of Probiota Americas.
https://probiotaamericas.com/live/en/page/sponsors
Should give FF a lot more industry exposure.
Another option was that trade was from last week when I picked a few up at .6455 and the ask was under .7p so an buy at that size would have been above the ask .!
To me it looks like a mid price trade minus a discount ! So some speculation that it is a buy , with no confirmation yet ! I am optimistically hopeful .
You may well think it, but you're in an evidence free zone.
All trades are transfers, between a buyer and a seller, with the MM's in the middle to create some level of liquidity.
That trade, at that price, could have been wither a buy or a sell, but there ought to be a balancing trade, MM's wouldn't keep one on the books for very long at all.
I think 28m is a transfer not sell. If the market is flooded with 28m shares for sale then the SP could be grounded below 0.5p (imho).
"Would be glad to hear a positive view that sounds realistic."
We are pretty much all long term holders here and beyond us this share is not on anyones radar. That will only change if money comes in. So the real question is why are we LTH still deciding to hold.
A) By-Health have spent significant money, carrying out 6 clinical trials and 2 animal studies to obtain a unique health claim for FF. This is being done to specially target one of the main cardiovascular disease risks 'platelet aggregation' that has been highlighted by the state in the Healthy China 2030 initiative. We believe by specifically addressing this risk, the Chinese state will provide assistance to By-Health by opening doors for them. I read somewhere that contributing to HC2030 opens up significant opportunities for companies.
B) According to articles we have found, By-Health have received strong interest from a large number of multi-national food and beverage companies. One article phrased it differently, saying that a large number of multi-national food and beverage companies have agreed to help with the commercialisation of Fruitflow in China.
C) The Chinese demand for Vitamins and Dietary supplements is huge and set to grow exponentially. By-Health have had a majorly successful quarter. They have said that Fruitflow will be the basis of their heart health range of products. Because of the Chinese regulatory model and list of approved health claims, there is not a lot around heart health. Then all companies end up with essentially the same product offerings. Fruitflow is about to be in a very unique position, a health claim all to itself (platelet aggregation), then eventually perhaps blood lipid regulation and blood pressure reduction too, perhaps. It's a massive opportunity, no other products can make the claim for at least 5 years.
D) DSM seem to be keen to commercialise Fruitflow based on its gut modulation and TMAO reduction. They claim that global companies are back on the scene. DSM themselves own massive gut health brands. We hope that between DMS owned brands and global companies, some of them move forward with FF.
E) The most populous country on earth is India. We understand from Asim Duttaroy that Fruitflow will be available there soon, but we don't know how.
F) There are ongoing trials in Bangladesh by the leading pharmaceutical company with a view to gaining regulatory approval. We assume this to be Square Pharmaceuticals, the biggest in Bangladesh.
G) Our understanding is that PXS have more prospective customers that are expected to soon be direct customers.
I) We will make more money on existing sales, building up over the next 4 years. We assume the sales are expected to be fairly good, given that they are opting to purchase circa £1m on stock from DSM. They have £500k worth and need to work out the best way of meeting the demands, either purchase from DSM or bake up a fresh batch. FF is high m
Forward selling, hope its not yorkville advisers
Usually a placing is notified before the trades hit the market.
But it's a chunky amount, and no way would MM's raise the Bid to accommodate that amount unless they has a sale for the shares
As that comes too 196k could be a placing !
28m just gone through not sure if it’s a buy or sell ,could be transfer.
Well I am hence increasing my holding to 15.2 million shares in the last week. Yes its frustrating waiting for all the news due to land but a lot is not in our hands. Must say I am frustrated with the funding hold up and have made my feelings clear to IF. I can understand why the hold up but its affecting confidence in PXS. But if the SP keeps dropping at times below 0.7 I will be topping up again